Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies

The Protein Data Bank

Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196 · see citing works

Continuous cultures of fused cells secreting antibody of predefined specificity

Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200 · see citing works

Protein Misfolding, Functional Amyloid, and Human Disease

Chiti, F., & Dobson, C. M. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.123901 · Cited by 6,435 · see citing works

Protein folding and misfolding

Dobson, C. M. (2003) · Nature · doi:10.1038/nature02261 · Cited by 4,791 · see citing works

Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface

Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143 · see citing works

DrugBank: a comprehensive resource for in silico drug discovery and exploration

Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892 · see citing works

Phage antibodies: filamentous phage displaying antibody variable domains

McCafferty, J., Griffiths, A. D., Winter, G. P., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,427 · see citing works

Introduction to Protein Structure

Brändén, C.-I., & Tooze, J. (2012) · Garland Science eBooks · doi:10.1201/9781136969898 · Cited by 2,398 · see citing works

Structure of the cross-β spine of amyloid-like fibrils

Nelson, R. A., Sawaya, M. R., Balbirnie, M., Madsen, A. Ø., Riekel, C., Grothe, R., & Eisenberg, D. S. (2005) · Nature · doi:10.1038/nature03680 · Cited by 2,205 · see citing works

Construction of Biologically Functional Bacterial Plasmids In Vitro

Cohen, S. N., Chang, A. C. Y., Boyer, H. W., & Helling, R. B. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.11.3240 · Cited by 1,811 · see citing works

Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins

Fernández‐Escamilla, A. M., Rousseau, F., Schymkowitz, J. W. H., & Serrano, L. G. (2004) · Nature Biotechnology · doi:10.1038/nbt1012 · Cited by 1,663 · see citing works

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Cho, H., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,615 · see citing works

Reshaping human antibodies for therapy

Riechmann, L., Clark, M., Waldmann, H., & Winter, G. P. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562 · see citing works

Replacing the complementarity-determining regions in a human antibody with those from a mouse

Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406 · see citing works

Effects of protein aggregates: An immunologic perspective

Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355 · see citing works

Glutamine Repeats and Neurodegeneration

Zoghbi, H. Y., & Orr, H. T. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.217 · Cited by 1,311 · see citing works

Monoclonal antibody therapy of cancer

Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,245 · see citing works

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P. H., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,117 · see citing works

Potent antibody therapeutics by design

Carter, P. J. (2006) · Nature reviews. Immunology · doi:10.1038/nri1837 · Cited by 1,103 · see citing works

Stability of Protein Pharmaceuticals

Manning, M. C., Patel, K., & Borchardt, R. T. (1989) · Pharmaceutical Research · doi:10.1023/a:1015929109894 · Cited by 1,082 · see citing works

Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases.

Perutz, M. F., Johnson, T., Suzuki, M., & Finch, J. T. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5355 · Cited by 1,060 · see citing works

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.21.6851 · Cited by 1,040 · see citing works

Review: history of the amyloid fibril.

Sipe, J., & Cohen, A. B. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4221 · Cited by 1,037 · see citing works

Conformational constraints for amyloid fibrillation: the importance of being unfolded

Uversky, V. N., & Fink, A. L. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.12.008 · Cited by 1,012 · see citing works

Protein aggregation and its inhibition in biopharmaceutics

Wang, W. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.11.014 · Cited by 990 · see citing works

Antibody Structure, Instability, and Formulation

Wang, W., Singh, S. K., Zeng, D. L., King, K., & Nema, S. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20727 · Cited by 948 · see citing works

Challenges in the development of high protein concentration formulations

Shire, S. J., Shahrokh, Z., & 刘, J. 军. L. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20079 · Cited by 886 · see citing works

Discovery and Development of the Complement Inhibitor Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · see citing works

Natural β-sheet proteins use negative design to avoid edge-to-edge aggregation

Richardson, J. S., & Richardson, D. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052706099 · Cited by 753 · see citing works

Monoclonal antibody successes in the clinic

Reichert, J. M., Rosensweig, C., Faden, L. B., & Dewitz, M. C. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1073 · Cited by 736 · see citing works

Proteins: Structures and molecular properties

Rb, F. (1985) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(85)90239-7 · Cited by 669 · see citing works

Challenges in the Development of High Protein Concentration Formulations

Shire, S. J., Shahrokh, Z., & Liu, J. (2009) · Springer eBooks · doi:10.1007/978-0-387-76643-0_9 · Cited by 657 · see citing works

Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus

Johnson, S., Oliver, C. N., Prince, G. A., Hemming, V. G., Pfarr, D. S., Wang, S., Dormitzer, M., O'Grady, J., Koenig, S., Tamura, J. K., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/514115 · Cited by 642 · see citing works

Structure-Immunogenicity Relationships of Therapeutic Proteins

Hermeling, S., Crommelin, D. J. A., Schellekens, H., & Jiskoot, W. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000029275.41323.a6 · Cited by 617 · see citing works

Production of functional chimaeric mouse/human antibody

Boulianne, G. L., Hozumi, N., & Shulman, M. J. (1984) · Nature · doi:10.1038/312643a0 · Cited by 554 · see citing works

Introduction to protein structure

Saffran, M. (1992) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(92)90006-m · Cited by 527 · see citing works

A census of glutamine/asparagine-rich regions: Implications for their conserved function and the prediction of novel prions

Michelitsch, M. D., & Weissman, J. S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.22.11910 · Cited by 463 · see citing works

Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson

Harris, L. J., Skaletsky, E., & McPherson, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1508 · Cited by 440 · see citing works

Prediction of Aggregation-Prone Regions in Structured Proteins

Tartaglia, G. G., Pawar, A. P., Campioni, S., Dobson, C. M., Chiti, F., & Vendruscolo, M. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.05.013 · Cited by 437 · see citing works

Human antibodies from transgenic animals.

Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434 · see citing works

Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc

Idusogie, E. E., Presta, L. G., Gazzano, H., Tótpál, K., Wong, P. Y., Ultsch, M. H., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424 · see citing works

Kinetic partitioning of protein folding and aggregation

Chiti, F., Taddei, N., Baroni, F., Capanni, C., Stefani, M., Ramponi, G., & Dobson, C. M. (2002) · Nature Structural Biology · doi:10.1038/nsb752 · Cited by 423 · see citing works

Analysis of the Minimal Amyloid-forming Fragment of the Islet Amyloid Polypeptide

Rosenfeld, R., & Gazit, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102883200 · Cited by 421 · see citing works

Antigen-specific human antibodies from mice comprising four distinct genetic modifications

Lönberg, N., Taylor, L. D., Harding, F., Trounstine, M. L., Higgins, K. M., Schramm, S. R., Kuo, C.-C., Mashayekh, R., Wymore, K., McCabe, J. G., et al. (1994) · Nature · doi:10.1038/368856a0 · Cited by 399 · see citing works

The 3D profile method for identifying fibril-forming segments of proteins

Thompson, M. J., Sievers, S. A., Karanicolas, J., Ivanova, M. I., Baker, D. A., & Eisenberg, D. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511295103 · Cited by 396 · see citing works

Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells

Yang, W. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.23.2905 · Cited by 371 · see citing works

Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv

Thomas, T. C., Rollins, S. A., Rother, R. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Nye, S. H., Matis, L. A., Squinto, S. P., & Evans, M. J. (1996) · Molecular Immunology · doi:10.1016/s0161-5890(96)00078-8 · Cited by 363 · see citing works

Antigen–specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

Green, L. L., Hardy, M. C., Maynard-Currie, C. E., Tsuda, H., Louie, D. M., Mendez, M. J., Abderrahim, H., Noguchi, M., Smith, D. H., Zeng, Y. C., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-13 · Cited by 355 · see citing works

Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity

Chen, S., Berthelier, V., Yang, W., & Wetzel, R. B. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4850 · Cited by 334 · see citing works

Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice

Braun, A. B., Kwee, L., Labow, M., & Alsenz, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012193326789 · Cited by 299 · see citing works

Antibody therapeutics:

Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294 · see citing works

Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 Subclass

Dillon, T. M., Ricci, M. S., Vezina, C., Flynn, G. C., Liu, Y. D., Rehder, D. S., Plant, M., Henkle, B., Li, Y., Deechongkit, S., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709988200 · Cited by 291 · see citing works

A hapten-specific chimaeric IgE antibody with human physiological effector function

Neuberger, M. S., Williams, G. T., Mitchell, E. B., Jouhal, S., Flanagan, J. G., & Rabbitts, T. H. (1985) · Nature · doi:10.1038/314268a0 · Cited by 289 · see citing works

Human IgG2 Antibodies Display Disulfide-mediated Structural Isoforms

Wypych, J., Li, M., Guo, A., Zhang, Z., Martinez, T., Allen, M. J., Fodor, S., Kelner, D. N., Flynn, G. C., Liu, D., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709987200 · Cited by 286 · see citing works

Amino Acid Contribution to Protein Solubility: Asp, Glu, and Ser Contribute more Favorably than the other Hydrophilic Amino Acids in RNase Sa

Trevino, S. R., Scholtz, J. M., & Pace, C. N. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.10.026 · Cited by 285 · see citing works

Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases

Chiti, F., Calamai, M., Taddei, N., Stefani, M., Ramponi, G., & Dobson, C. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212527999 · Cited by 272 · see citing works

Human Antibody Effector Function

Burton, D. R., & Woof, J. M. (1992) · Advances in immunology · doi:10.1016/s0065-2776(08)60486-1 · Cited by 266 · see citing works

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 å resolution and mutational analysis of the interface

Muller, Y. A., Chen, Y., Christinger, H. W., Li, B., Cunningham, B. C., Lowman, H. B., & de Vos, A. M. (1998) · Structure · doi:10.1016/s0969-2126(98)00116-6 · Cited by 263 · see citing works

Molecular conformation of a peptide fragment of transthyretin in an amyloid fibril

Jaroniec, C. P., MacPhee, C. E., Astrof, N. S., Dobson, C. M., & Griffin, R. G. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252625999 · Cited by 253 · see citing works

Contrasting IgG structures reveal extreme asymmetry and flexibility.

Saphire, E., Stanfield, R., Maxcrispin, M., Parren, P., Rudd, P., Dwek, R., Burton, D., & Wilson, I. A. G. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00244-9 · Cited by 249 · see citing works

Aspects on human amyloid forms and their fibril polypeptides

Westermark, P. (2005) · FEBS Journal · doi:10.1111/j.1742-4658.2005.05024.x · Cited by 248 · see citing works

Prevention of amyloid‐like aggregation as a driving force of protein evolution

Monsellier, É., & Chiti, F. (2007) · EMBO Reports · doi:10.1038/sj.embor.7401034 · Cited by 238 · see citing works

The three-dimensional structure of an intact monoclonal antibody for canine lymphoma

Harris, L. J., Larson, S. B., Hasel, K. W., Day, J. S., Greenwood, A., & McPherson, A. (1992) · Nature · doi:10.1038/360369a0 · Cited by 217 · see citing works

Prediction of aggregation rate and aggregation‐prone segments in polypeptide sequences

Tartaglia, G. G., Cavalli, A., Pellarin, R., & Caflisch, A. (2005) · Protein Science · doi:10.1110/ps.051471205 · Cited by 214 · see citing works

Prediction of "hot spots" of aggregation in disease-linked polypeptides

de Groot, N. S., Pallarès, I., Avilés, F. X., Vendrell, J., & Ventura, S. (2005) · BMC Structural Biology · doi:10.1186/1472-6807-5-18 · Cited by 205 · see citing works

Therapeutic antibody expression technology

Chadd, H. E., & Chamow, S. M. (2001) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00198-1 · Cited by 205 · see citing works

Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases

Kelly, J. W. (1997) · Structure · doi:10.1016/s0969-2126(97)00215-3 · Cited by 205 · see citing works

Generic hydrophobic residues are sufficient to promote aggregation of the Alzheimer's Aβ42 peptide

Kim, W., & Hecht, M. H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605629103 · Cited by 191 · see citing works

Crystal structure of the human T cell receptor CD3εγ heterodimer complexed to the therapeutic mAb OKT3

Kjer‐Nielsen, L., Dunstone, M. A., Kostenko, L., Ely, L. K., Beddoe, T., Mifsud, N. A., Purcell, A. W., Brööks, A. G., McCluskey, J., & Rossjohn, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402295101 · Cited by 182 · see citing works

A Role for Protein Misfolding in Immunogenicity of Biopharmaceuticals

Maas, C., Hermeling, S., Bouma, B., Jiskoot, W., & Gebbink, M. F. B. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605984200 · Cited by 157 · see citing works

Amyloid fibrils formation and amorphous aggregation in concanavalin A

Vetri, V., Canale, C., Relini, A., Librizzi, F., Militello, V., Gliozzi, A., & Leone, M. (2006) · Biophysical Chemistry · doi:10.1016/j.bpc.2006.07.012 · Cited by 151 · see citing works

Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1

Werther, W., González, T., O'Connor, S. L., McCabe, S., Chan, B., Hotaling, T. E., Champe, M., Fox, J. A., Jardieu, P. M., Berman, P. W., et al. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4986 · Cited by 148 · see citing works

Amyloid-forming Peptides from β2-Microglobulin—Insights into the Mechanism of Fibril Formation in Vitro

Jones, S., Manning, J., Kad, N. M., & Radford, S. E. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01227-5 · Cited by 148 · see citing works

Chimeric and humanized antibodies with specificity for the CD33 antigen

Co, M. S., Avdalovic, N. M., Caron, P. C., Avdalovic, M. V., Scheinberg, D. A., & Queen, C. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.4.1149 · Cited by 147 · see citing works

Aggregation of globular proteins

Young, L. R. D., Fink, A. L., & Dill, K. A. (1993) · Accounts of Chemical Research · doi:10.1021/ar00036a002 · Cited by 146 · see citing works

Immunogenicity of therapeutic monoclonal antibodies.

Pendley, C. E., Schantz, A., & Wagner, C. (2003) · PubMed · Cited by 144 · see citing works

Assessing the role of aromatic residues in the amyloid aggregation of human muscle acylphosphatase

Bemporad, F., Taddei, N., Stefani, M., & Chiti, F. (2006) · Protein Science · doi:10.1110/ps.051915806 · Cited by 120 · see citing works

Atomistic Simulations of the Effects of Polyglutamine Chain Length and Solvent Quality on Conformational Equilibria and Spontaneous Homodimerization

Vitalis, A., Wang, X., & Pappu, R. V. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.026 · Cited by 116 · see citing works

Protein Formulation and Delivery

(2007) · CRC Press eBooks · doi:10.3109/9780849379529 · Cited by 110 · see citing works

Antibody structure

Davies, D. R., & Chacko, S. (1993) · Accounts of Chemical Research · doi:10.1021/ar00032a005 · Cited by 108 · see citing works

Opalescent Appearance of an IgG1 Antibody at High Concentrations and Its Relationship to Noncovalent Association

Sukumar, M., Doyle, B. L., Combs, J. L., & Pekar, A. H. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000032993.98705.73 · Cited by 107 · see citing works

Latest technologies for the enhancement of antibody affinity

Wark, K. L., & Hudson, P. J. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.01.025 · Cited by 99 · see citing works

Decrease in Protein Solubility and Cataract Formation Caused by the Pro23 to Thr Mutation in Human γD-Crystallin,

Pande, A., Annunziata, O., Asherie, N., Ogun, O. O., Benedek, G. B., & Pande, J. (2005) · Biochemistry · doi:10.1021/bi0479611 · Cited by 95 · see citing works

Upping the ante on antibodies

Baker, M. (2005) · Nature Biotechnology · doi:10.1038/nbt0905-1065 · Cited by 90 · see citing works

Generation of Recombinant Antibodies

Kipriyanov, S. M., & Little, M. (1999) · Molecular Biotechnology · doi:10.1385/mb:12:2:173 · Cited by 80 · see citing works

Disulfide Connectivity of Human Immunoglobulin G2 Structural Isoforms

Martinez, T., Guo, A. X., Allen, M. J., Han, M., Pace, D. L., Jones, J. B., Gillespie, R., Ketchem, R. R., Zhang, Y., & Balland, A. (2008) · Biochemistry · doi:10.1021/bi800576c · Cited by 80 · see citing works

Yeast Prions and Their Prion-Forming Domain

Tuite, M. F. (2000) · Cell · doi:10.1016/s0092-8674(00)80663-7 · Cited by 78 · see citing works

Human Immunoglobulin G2 (IgG2) and IgG4, but Not IgG1 or IgG3, Protect Mice against Cryptococcus neoformans Infection

Beenhouwer, D. O., Yoo, E. M., Lai, C. W., Rocha, M. A., & Morrison, S. L. (2007) · Infection and Immunity · doi:10.1128/iai.01161-06 · Cited by 75 · see citing works

Characterization of a possible amyloidogenic precursor in glutamine-repeat neurodegenerative diseases

Armen, R. S., Bernard, B. M., Day, R. J., Alonso, D. O. V., & Daggett, V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502068102 · Cited by 72 · see citing works

Tertiary structure of human γ6 light chains

Pokkuluri, P. R., Solomon, A., Weiss, D. T., Stevens, F. J., & Schiffer, M. (1999) · Amyloid · doi:10.3109/13506129909007322 · Cited by 61 · see citing works

β Edge strands in protein structure prediction and aggregation

Siepen, J. A., Radford, S. E., & Westhead, D. R. (2003) · Protein Science · doi:10.1110/ps.03234503 · Cited by 57 · see citing works

Phage Display: A Molecular Tool for the Generation of Antibodies— A Review

Schmitz, U., Versmold, A., Kaufmann, P., & Frank, H. (2000) · Placenta · doi:10.1053/plac.1999.0511 · Cited by 54 · see citing works

Structural differences between the repertoires of mouse and human germline genes and their evolutionary implications

Almagro, J. C., Hernández, I., Ramírez, M. C., & Vargas‐Madrazo, E. (1998) · Immunogenetics · doi:10.1007/s002510050370 · Cited by 54 · see citing works

Consensus features in amyloid fibrils: sheet–sheet recognition via a (polar or nonpolar) zipper structure

Zheng, J., Ma, B., & Nussinov, R. (2006) · Physical Biology · doi:10.1088/1478-3975/3/3/p01 · Cited by 53 · see citing works

Inter Heavy–Light Chain Disulphide Bridge in Immune Globulins

Pink, J. R. L., & Milstein, C. (1967) · Nature · doi:10.1038/214092a0 · Cited by 48 · see citing works

Intrachain disulphide bridges in immunoglobulin G heavy chains. The Fc fragment

Frangione, B., Milstein, C., & Franklin, E. C. (1968) · Biochemical Journal · doi:10.1042/bj1060015 · Cited by 48 · see citing works

1.9 Å structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen

James, L. C., Hale, G., Waldman, H., & Bloomer, A. C. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2750 · Cited by 47 · see citing works

Humanized porcine VCAM-specific monoclonal antibodies with chimeric IgG2/G4 constant regions block human leukocyte binding to porcine endothelial cells

Mueller, J. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Squinto, S. P., Matis, L. A., & Evans, M. J. (1997) · Molecular Immunology · doi:10.1016/s0161-5890(97)00042-4 · Cited by 46 · see citing works

The Yeast Prion Ure2p Native-like Assemblies Are Toxic to Mammalian Cells Regardless of Their Aggregation State

Pieri, L., Bucciantini, M., Nosi, D., Formigli, L., Savistchenko, J., Melki, R., & Stefani, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511647200 · Cited by 44 · see citing works

Sequence and Structure Analysis of Parallel β Helices: Implication for Constructing Amyloid Structural Models

Tsai, H. G., Gunasekaran, K., & Nussinov, R. (2006) · Structure · doi:10.1016/j.str.2006.03.015 · Cited by 43 · see citing works

Three-dimensional structure of an immunoglobulin light-chain dimer with amyloidogenic properties

Bourne, P. C., Ramsland, P. A., Shan, L., Fan, Z.-C., DeWitt, C. R., Shultz, B. B., Terzyan, S. S., Moomaw, C. R., Slaughter, C. A., Guddat, L. W., et al. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902004183 · Cited by 43 · see citing works

Attacking Amyloid

Kelly, J. W. (2005) · New England Journal of Medicine · doi:10.1056/nejmcibr044231 · Cited by 21 · see citing works

Structure of the Fab Fragment of SDZ CHI621: a Chimeric Antibody Against CD25

Mikol, V. (1996) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996000704 · Cited by 9 · see citing works

Humanization of a mouse neutralizing monoclonal antibody against tumor necrosis factor-α (TNF-α)

Nagahira, K., Fukuda, Y., Oyama, Y., Kurihara, T., Nasu, T., Kawashima, H., Noguchi, C., Oikawa, S., & Nakanishi, T. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00184-7 · Cited by 5 · see citing works

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 760 · see citing works

Immunogenicity of therapeutic proteins: Influence of aggregation

Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. (2013) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.821564 · Cited by 596 · see citing works

The CamSol method of rational design of protein mutants with enhanced solubility

Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.09.026 · Cited by 494 · see citing works

Aggregates in monoclonal antibody manufacturing processes

Vázquez‐Rey, M., & Lang, D. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23155 · Cited by 480 · see citing works

Therapeutic protein aggregation: mechanisms, design, and control

Roberts, C. J. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.05.005 · Cited by 455 · see citing works

Impact of Product-Related Factors on Immunogenicity of Biotherapeutics

Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350 · see citing works

A Consensus Method for the Prediction of ‘Aggregation-Prone’ Peptides in Globular Proteins

Tsolis, A. C., Papandreou, N. C., Iconomidou, V. A., & Hamodrakas, S. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054175 · Cited by 324 · see citing works

The state-of-play and future of antibody therapeutics

Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., & Kayser, V. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.004 · Cited by 318 · see citing works

Comparative Effects of pH and Ionic Strength on Protein–Protein Interactions, Unfolding, and Aggregation for IgG1 Antibodies

Şahin, E., Grillo, A. O., Perkins, M. D., & Roberts, C. J. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22198 · Cited by 247 · see citing works

Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications

Kuriakose, A., Chirmule, N. B., & Nair, P. (2016) · Journal of Immunology Research · doi:10.1155/2016/1298473 · Cited by 231 · see citing works

Computational approaches to therapeutic antibody design: established methods and emerging trends

Norman, R. A., Ambrosetti, F., Bonvin, A. M. J. J., Colwell, L. J., Kelm, S., Kumar, S., & Krawczyk, K. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz095 · Cited by 219 · see citing works

Prediction of aggregation prone regions of therapeutic proteins

Chennamsetty, N., Voynov, V., Kayser, V., Helk, B., & Trout, B. L. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp911706q · Cited by 200 · see citing works

General strategy for the generation of human antibody variable domains with increased aggregation resistance

Dudgeon, K., Rouet, R., Kokmeijer, I., Schofield, P., Stolp, J., Langley, D. B., Stock, D., & Christ, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202866109 · Cited by 185 · see citing works

Impact of freezing on pH of buffered solutions and consequences for monoclonal antibody aggregation

Kolhe, P., Amend, E., & Singh, S. K. (2009) · Biotechnology Progress · doi:10.1002/btpr.377 · Cited by 174 · see citing works

Posttranslational Modifications and the Immunogenicity of Biotherapeutics

Jefferis, R. (2016) · Journal of Immunology Research · doi:10.1155/2016/5358272 · Cited by 158 · see citing works

Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility

Rabia, L. A., Desai, A. A., Jhajj, H. S., & Tessier, P. M. (2018) · Biochemical Engineering Journal · doi:10.1016/j.bej.2018.06.003 · Cited by 159 · see citing works

Distinct Aggregation Mechanisms of Monoclonal Antibody Under Thermal and Freeze-Thaw Stresses Revealed by Hydrogen Exchange

Zhang, A., Singh, S. K., Shirts, M. R., Kumar, S., & Fernández, E. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0538-y · Cited by 156 · see citing works

Antibody Aggregation: Insights from Sequence and Structure

Li, W., Prabakaran, P., Chen, W., Zhu, Z., Feng, Y., & Dimitrov, D. S. (2016) · Antibodies · doi:10.3390/antib5030019 · Cited by 152 · see citing works

Advances and challenges in analytical characterization of biotechnology products: Mass spectrometry-based approaches to study properties and behavior of protein therapeutics

Kaltashov, I. A., Bobst, C. E., Abzalimov, R. R., Wang, G., Baykal, B., & Wang, S. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.05.006 · Cited by 149 · see citing works

Elucidation of Acid-induced Unfolding and Aggregation of Human Immunoglobulin IgG1 and IgG2 Fc

Latypov, R. F., Hogan, S., Lau, H., Gadgil, H. S., & Liu, D. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.297697 · Cited by 148 · see citing works

Predicting solution aggregation rates for therapeutic proteins: Approaches and challenges

Roberts, C. J., Das, T. K., & Şahin, E. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.03.064 · Cited by 141 · see citing works

Aggregation in Protein-Based Biotherapeutics: Computational Studies and Tools to Identify Aggregation-Prone Regions

Agrawal, N. J., Kumar, S., Wang, X., Helk, B., Singh, S. K., & Trout, B. L. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22705 · Cited by 139 · see citing works

Concentration Dependent Viscosity of Monoclonal Antibody Solutions: Explaining Experimental Behavior in Terms of Molecular Properties

Li, L., Kumar, S., Buck, P. M., Burns, C., Lavoie, J., Singh, S. K., Warne, N. W., Nichols, P., Luksha, N., & Boardman, D. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1409-0 · Cited by 133 · see citing works

Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture

Pollock, J., Bolton, G., Coffman, J., Ho, S. V., Bracewell, D. G., & Farid, S. S. (2013) · Journal of Chromatography A · doi:10.1016/j.chroma.2013.01.082 · Cited by 133 · see citing works

Nonnative Aggregation of an IgG1 Antibody in Acidic Conditions: Part 1. Unfolding, Colloidal Interactions, and Formation of High-Molecular-Weight Aggregates

Brummitt, R. K., Nesta, D. P., Chang, L., Chase, S. F., Laue, T. M., & Roberts, C. J. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22448 · Cited by 125 · see citing works

Analytical characterization of biosimilar antibodies and Fc-fusion proteins

Beck, A., Diemer, H., Ayoub, D., Debaene, F., Wagner‐Rousset, E., Carapito, C., DORSSELAER, A. V., & Cianférani, S. (2013) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2013.02.014 · Cited by 119 · see citing works

Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies

Akbar, R., Bashour, H., Rawat, P., Robert, P. A., Smorodina, E., Cotet, T., Karlsen, K. F., Frank, R., Mehta, B. B., Vu, M. H., et al. (2022) · mAbs · doi:10.1080/19420862.2021.2008790 · Cited by 117 · see citing works

Effects of Salts from the Hofmeister Series on the Conformational Stability, Aggregation Propensity, and Local Flexibility of an IgG1 Monoclonal Antibody

Majumdar, R., Manikwar, P., Hickey, J. M., Samra, H. S., Sathish, H. A., Bishop, S. M., Middaugh, C. R., Volkin, D. B., & Weis, D. D. (2013) · Biochemistry · doi:10.1021/bi400232p · Cited by 114 · see citing works

Engineering Aggregation-Resistant Antibodies

Perchiacca, J. M., & Tessier, P. M. (2012) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-062011-081052 · Cited by 114 · see citing works

Solubility-Weighted Index: fast and accurate prediction of protein solubility

Bhandari, B. K., Gardner, P. P., & Lim, C. S. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa578 · Cited by 97 · see citing works

Stability engineering of the human antibody repertoire

Rouet, R., Lowe, D., & Christ, D. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.11.029 · Cited by 112 · see citing works

Aggregation risk prediction for antibodies and its application to biotherapeutic development

Obrezanova, O., Arnell, A., de la Cuesta, R. G., Berthelot, M. E., Gallagher, T. R., Zurdo, J., & Stallwood, Y. (2015) · mAbs · doi:10.1080/19420862.2015.1007828 · Cited by 107 · see citing works

Discovery and Characterization of a Photo-Oxidative Histidine-Histidine Cross-Link in IgG1 Antibody Utilizing 18O-Labeling and Mass Spectrometry

Liu, M., Zhang, Z., Cheetham, J., Ren, D., & Zhou, Z. S. (2014) · Analytical Chemistry · doi:10.1021/ac500334k · Cited by 107 · see citing works

Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins

Jarvi, N. L., & Balu‐Iyer, S. V. (2021) · BioDrugs · doi:10.1007/s40259-020-00465-4 · Cited by 105 · see citing works

Aggregation of therapeutic proteins

Wang, W., & Roberts, C. J. (2010) · Wiley eBooks · Cited by 104 · see citing works

Host cell protein adsorption characteristics during protein a chromatography

Tarrant, R. D. R., Velez‐Suberbie, M. L., Tait, A. S., Smales, C. M., & Bracewell, D. G. (2012) · Biotechnology Progress · doi:10.1002/btpr.1581 · Cited by 98 · see citing works

Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab

Courtois, F., Agrawal, N. J., Lauer, T. M., & Trout, B. L. (2015) · mAbs · doi:10.1080/19420862.2015.1112477 · Cited by 99 · see citing works

Nonnative Aggregation of an IgG1 Antibody in Acidic Conditions, Part 2: Nucleation and Growth Kinetics with Competing Growth Mechanisms

Brummitt, R. K., Nesta, D. P., Chang, L., Kroetsch, A. M., & Roberts, C. J. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22447 · Cited by 93 · see citing works

Toward aggregation-resistant antibodies by design

Lee, C. C., Perchiacca, J. M., & Tessier, P. M. (2013) · Trends in biotechnology · doi:10.1016/j.tibtech.2013.07.002 · Cited by 92 · see citing works

Aggregation of anti-streptavidin immunoglobulin gamma‐1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration

Kim, N., Remmele, R. L., Liu, D., Razinkov, V. I., Fernández, E., & Roberts, C. J. (2012) · Biophysical Chemistry · doi:10.1016/j.bpc.2012.12.004 · Cited by 90 · see citing works

Investigating Monoclonal Antibody Aggregation Using a Combination of H/DX-MS and Other Biophysical Measurements

Iacob, R. E., Bou-Assaf, G. M., Makowski, L., Engen, J. R., Berkowitz, S. A., & Houde, D. J. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23754 · Cited by 88 · see citing works

Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions

Kumar, S., Singh, S. K., Wang, X., Rup, B., & Gill, D. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0414-9 · Cited by 85 · see citing works

Selecting and engineering monoclonal antibodies with drug-like specificity

Starr, C. G., & Tessier, P. M. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.008 · Cited by 81 · see citing works

Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis

Wang, X., Singh, S. K., & Kumar, S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0143-5 · Cited by 79 · see citing works

Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-association of an IgG1 monoclonal antibody

Arora, J., Hickey, J. M., Majumdar, R., Esfandiary, R., Bishop, S. M., Samra, H. S., Middaugh, C. R., Weis, D. D., & Volkin, D. B. (2015) · mAbs · doi:10.1080/19420862.2015.1029217 · Cited by 76 · see citing works

Competing aggregation pathways for monoclonal antibodies

Wu, H., Kroe‐Barrett, R., Singh, S., Robinson, A. S., & Roberts, C. J. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.01.051 · Cited by 77 · see citing works

Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation

Hamrang, Z., Rattray, N. J. W., & Pluen, A. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.05.004 · Cited by 75 · see citing works

Full validation of therapeutic antibody sequences by middle-up mass measurements and middle-down protein sequencing

Resemann, A., Jabs, W., Wiechmann, A., Wagner, E., Colas, O., Evers, W., Belau, E., Vorwerg, L., Evans, C. S., Beck, A., et al. (2016) · mAbs · doi:10.1080/19420862.2015.1128607 · Cited by 73 · see citing works

Antibody informatics for drug discovery

Shirai, H., Prades, C., Vita, R., Marcatili, P., Popovic, B., Xu, J., Overington, J. P., Hirayama, K., Soga, S., Tsunoyama, K., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.07.006 · Cited by 73 · see citing works

Host cell protein removal from biopharmaceutical preparations: Towards the implementation of quality by design

Goey, C. H., Alhuthali, S., & Kontoravdi, C. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.03.021 · Cited by 72 · see citing works

Toward Drug-Like Multispecific Antibodies by Design

Sawant, M. S., Streu, C. N., Wu, L., & Tessier, P. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207496 · Cited by 74 · see citing works

Disulfide Bond Formation in the Periplasm of Escherichia coli

Manta, B., Boyd, D. H., & Berkmen, M. (2019) · EcoSal Plus · doi:10.1128/ecosalplus.esp-0012-2018 · Cited by 69 · see citing works

Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs

Tiller, K. E., Li, L., Kumar, S., Julian, M. C., Garde, S., & Tessier, P. M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.783837 · Cited by 71 · see citing works

Armoring the Interface with Surfactants to Prevent the Adsorption of Monoclonal Antibodies

Kanthe, A. D., Krause, M. E., Zheng, S., Ilott, A. J., Li, J., Bu, W., Bera, M. K., Lin, B., Maldarelli, C., & Tu, R. S. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b21979 · Cited by 69 · see citing works

Structural analysis of a therapeutic monoclonal antibody dimer by hydroxyl radical footprinting

Deperalta, G., Alvarez, M., Bechtel, C., Dong, K. C., McDonald, R., & Ling, V. W. T. (2013) · mAbs · doi:10.4161/mabs.22964 · Cited by 68 · see citing works

Protein aggregation: in silico algorithms and applications

Prabakaran, R., Rawat, P., Thangakani, A. M., Kumar, S., & Gromiha, M. M. (2021) · Biophysical Reviews · doi:10.1007/s12551-021-00778-w · Cited by 67 · see citing works

Improving Monoclonal Antibody Selection and Engineering using Measurements of Colloidal Protein Interactions

Geng, S. B., Cheung, J. K., Narasimhan, C. N., Shameem, M., & Tessier, P. M. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24130 · Cited by 65 · see citing works

Aggregation and pH–Temperature Phase Behavior for Aggregates of an IgG2 Antibody

Şahin, E., Weiss, W. F., Kroetsch, A. M., King, K. R., Kessler, R. K., Das, T. K., & Roberts, C. J. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23056 · Cited by 64 · see citing works

In silico methods for design of biological therapeutics

Roy, A., Nair, S. A., Sen, N., Soni, N., & Madhusudhan, M. S. (2017) · Methods · doi:10.1016/j.ymeth.2017.09.008 · Cited by 62 · see citing works

Developability assessment as an early de-risking tool for biopharmaceutical development

Zurdo, J. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.3 · Cited by 63 · see citing works

Prediction of delayed retention of antibodies in hydrophobic interaction chromatography from sequence using machine learning

Jain, T., Boland, T., Lilov, A., Burnina, I., Brown, M., Xu, Y., & Vásquez, M. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx519 · Cited by 61 · see citing works

Optimal charged mutations in the complementarity-determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold

Perchiacca, J. M., Lee, C. C., & Tessier, P. M. (2014) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt058 · Cited by 61 · see citing works

Computational Methods to Predict Therapeutic Protein Aggregation

Buck, P. M., Kumar, S., Wang, X., Agrawal, N. J., Trout, B. L., & Singh, S. K. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-921-1_26 · Cited by 60 · see citing works

On the Role of Aggregation Prone Regions in Protein Evolution, Stability, and Enzymatic Catalysis: Insights from Diverse Analyses

Buck, P. M., Kumar, S., & Singh, S. K. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003291 · Cited by 59 · see citing works

The effect of charge mutations on the stability and aggregation of a human single chain Fv fragment

Austerberry, J. I., Dajani, R., Panova, S., Roberts, D., Golovanov, A. P., Pluen, A., van der Walle, C. F., Uddin, S., Warwicker, J., Derrick, J. P., et al. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.01.019 · Cited by 60 · see citing works

Sequence features of variable region determining physicochemical properties and polyreactivity of therapeutic antibodies

Lecerf, M., Kanyavuz, A., Lacroix‐Desmazes, S., & Dimitrov, J. D. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.06.012 · Cited by 56 · see citing works

Refolding of biotech therapeutic proteins expressed in bacteria: review

Rathore, A. S., Bade, P. D., Joshi, V. S., Pathak, M., & Pattanayek, S. K. (2013) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.4152 · Cited by 55 · see citing works

Comparison of hydrophobicity scales for predicting biophysical properties of antibodies

Waibl, F., Fernández‐Quintero, M. L., Wedl, F. S., Kettenberger, H., Georges, G. J., & Liedl, K. R. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.960194 · Cited by 46 · see citing works

Computational Design and Biophysical Characterization of Aggregation-Resistant Point Mutations for γD Crystallin Illustrate a Balance of Conformational Stability and Intrinsic Aggregation Propensity

Şahin, E., Jordan, J. L., Spatara, M. L., Naranjo, A., Costanzo, J. A., Weiss, W. F., Robinson, A. S., Fernández, E., & Roberts, C. J. (2010) · Biochemistry · doi:10.1021/bi100978r · Cited by 49 · see citing works

In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development

Steven, J., Müller, M. R., Carvalho, M. F., Ubah, O. C., Kovaleva, M., Donohoe, G. G., Baddeley, T. C., Cornock, D., Saunders, K. C., Porter, A. J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01361 · Cited by 49 · see citing works

Encapsulated Cellular Implants for Recombinant Protein Delivery and Therapeutic Modulation of the Immune System

Lathuilière, A., Mach, N., & Schneider, B. L. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160510578 · Cited by 47 · see citing works

Developability considerations for bispecific and multispecific antibodies

Amash, A., Volkers, G., Farber, P. J., Griffin, D., Davison, K. S., Goodman, A., Tonikian, R., Yamniuk, A. P., Barnhart, B. C., & Jacobs, T. M. (2024) · mAbs · doi:10.1080/19420862.2024.2394229 · Cited by 50 · see citing works

Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development

Salazar‐Fontana, L. I., Desai, D. D., Khan, T. A., Pillutla, R. C., Prior, S., Ramakrishnan, R., Schneider, J., & Joseph, A. M. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0030-z · Cited by 46 · see citing works

Effect of Peroxide- Versus Alkoxyl-Induced Chemical Oxidation on the Structure, Stability, Aggregation, and Function of a Therapeutic Monoclonal Antibody

Shah, D. D., Zhang, J., Hsieh, M.-C., Sundaram, S., Maity, H., & Mallela, K. M. G. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.07.024 · Cited by 46 · see citing works

Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques

Fang, J. S., Doneanu, C. E., Alley, W. R., Yu, Y. Q., Beck, A., & Chen, W. (2016) · mAbs · doi:10.1080/19420862.2016.1193661 · Cited by 45 · see citing works

In Silico Prediction of Diffusion Interaction Parameter (kD), a Key Indicator of Antibody Solution Behaviors

Tomar, D. S., Singh, S. K., Li, L., Broulidakis, M. P., & Kumar, S. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2466-6 · Cited by 45 · see citing works

Masking of the Fc region in human IgG4 by constrained X-ray scattering modelling: implications for antibody function and therapy

Abe, Y., Gor, J., Bracewell, D. G., Perkins, S. J., & Dalby, P. A. (2010) · Biochemical Journal · doi:10.1042/bj20100641 · Cited by 44 · see citing works

Continuous capture of recombinant antibodies by ZnCl2 precipitation without polyethylene glycol

Dutra, G., Komuczki, D., Jungbauer, A., & Satzer, P. (2020) · Engineering in Life Sciences · doi:10.1002/elsc.201900160 · Cited by 43 · see citing works

Leveraging SBDD in Protein Therapeutic Development: Antibody Engineering

Gilliland, G. L., Luo, J., Vafa, O., & Almagro, J. C. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-520-6_14 · Cited by 42 · see citing works

Rational Design of Biobetters with Enhanced Stability

Courtois, F., Schneider, C. P., Agrawal, N. J., & Trout, B. L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24520 · Cited by 42 · see citing works

Application of machine learning to predict monomer retention of therapeutic proteins after long term storage

Gentiluomo, L., Roessner, D., & Frieß, W. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119039 · Cited by 40 · see citing works

Impact of deglycosylation and thermal stress on conformational stability of a full length murine igG2a monoclonal antibody: Observations from molecular dynamics simulations

Wang, X., Kumar, S., Buck, P. M., & Singh, S. K. (2012) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24202 · Cited by 39 · see citing works

Capillary zone electrophoresis-native mass spectrometry for the quality control of intact therapeutic monoclonal antibodies

Le-Minh, V., Tran, N. T., Makky, A., Rosilio, V., Taverna, M., & Smadja, C. (2019) · Journal of Chromatography A · doi:10.1016/j.chroma.2019.05.050 · Cited by 39 · see citing works

The Solution Structure of Rabbit IgG Accounts for Its Interactions with the Fc Receptor and Complement C1q and Its Conformational Stability

Rayner, L., Kadkhodayi-Kholghi, N., Heenan, R. K., Gor, J., Dalby, P. A., & Perkins, S. J. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.11.019 · Cited by 38 · see citing works

Identification of properties important to protein aggregation using feature selection

Fang, Y., Gao, S., Tai, D., Middaugh, C. R., & Fang, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-314 · Cited by 37 · see citing works

The Fab Conformations in the Solution Structure of Human Immunoglobulin G4 (IgG4) Restrict Access to Its Fc Region

Rayner, L., Hui, G. K., Gor, J., Heenan, R. K., Dalby, P. A., & Perkins, S. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.572404 · Cited by 36 · see citing works

MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity

Sekiguchi, N., Kubo, C., Takahashi, A., Muraoka, K., Takeiri, A., Ito, S., Yano, M., Mimoto, F., Maeda, A., Iwayanagi, Y., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1518888 · Cited by 36 · see citing works

Correlating the Effects of Antimicrobial Preservatives on Conformational Stability, Aggregation Propensity, and Backbone Flexibility of an IgG1 mAb

Arora, J., Joshi, S. B., Middaugh, C. R., Weis, D. D., & Volkin, D. B. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.02.007 · Cited by 35 · see citing works

Immunogenicity of Bioproducts: Cellular Models to Evaluate the Impact of Therapeutic Antibody Aggregates

Nabhan, M., Pallardy, M. J., & Turbica, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00725 · Cited by 35 · see citing works

Generation and functional characterization of a single-chain variable fragment (scFv) of the anti-FGF2 3F12E7 monoclonal antibody

de Aguiar, R. B., da Silva, T. D. A., Costa, B. A., Marcondes, M. F., Yamada, R. Y., Braggion, C., Perez, K. R., Mori, M. A. S., Oliveira, V., & de Moraes, J. Z. (2021) · Scientific Reports · doi:10.1038/s41598-020-80746-8 · Cited by 35 · see citing works

Extending the limits of size exclusion chromatography: Simultaneous separation of free payloads and related species from antibody drug conjugates and their aggregates

Goyon, A., Sciascera, L., Clarke, A. M., Guillarme, D., & Pell, R. (2018) · Journal of Chromatography A · doi:10.1016/j.chroma.2018.01.039 · Cited by 34 · see citing works

Relation of Colloidal and Conformational Stabilities to Aggregate Formation in a Monoclonal Antibody

Oyama, H., Koga, H., Tadokoro, T., Maenaka, K., Shiota, A., Yokoyama, M., Noda, M., Torisu, T., & Uchiyama, S. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.038 · Cited by 34 · see citing works

Exploring the sequence features determining amyloidosis in human antibody light chains

Rawat, P., Prabakaran, R., Kumar, S., & Gromiha, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-93019-9 · Cited by 34 · see citing works

Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: implications for rational design of novel and follow-on therapeutic antibodies

Kumar, S., Mitchell, M. A., Rup, B., & Singh, S. K. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23169 · Cited by 33 · see citing works

Engineered Autonomous Human Variable Domains

Nilvebrant, J., Tessier, P. M., & Sidhu, S. S. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160921143011 · Cited by 32 · see citing works

Advanced computational approaches to understand protein aggregation

Ghosh, D., Biswas, A., & Radhakrishna, M. (2024) · Biophysics Reviews · doi:10.1063/5.0180691 · Cited by 31 · see citing works

Aggregation prone regions in human proteome: Insights from large‐scale data analyses

Prabakaran, R., Goel, D., Kumar, S., & Gromiha, M. M. (2017) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25276 · Cited by 31 · see citing works

Covalent labeling and mass spectrometry reveal subtle higher order structural changes for antibody therapeutics

Limpikirati, P. K., Hale, J. E., Hazelbaker, M. A., Huang, Y., Jia, Z., Yazdani, M., Graban, E. M., Vaughan, R. C., & Vachet, R. W. (2019) · mAbs · doi:10.1080/19420862.2019.1565748 · Cited by 30 · see citing works

Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs

Mills, B. J., Kruger, T. M., Bruncko, M., Zhang, X., & Jameel, F. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.01.029 · Cited by 29 · see citing works

High Throughput Prediction Approach for Monoclonal Antibody Aggregation at High Concentration

Zidar, M., Šušterič, A., Ravnik, M., & Kuzman, D. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2191-6 · Cited by 28 · see citing works

Aggregation in Protein-Based Biotherapeutics: Computational Studies and Tools to Identify Aggregation-Prone Regions

Agrawal, N. J., Kumar, S., Wang, X., Helk, B., Singh, S. K., & Trout, B. L. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22705 · Cited by 139 · see citing works

Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis

Wang, X., Singh, S. K., & Kumar, S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0143-5 · Cited by 79 · see citing works

Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions

Kumar, S., Singh, S. K., Wang, X., Rup, B., & Gill, D. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0414-9 · Cited by 85 · see citing works

Remediating agitation-induced antibody aggregation by eradicating exposed hydrophobic motifs

Clark, R. H., Latypov, R. F., Imus, C. D., Carter, J. V., Wilson, Z., Manchulenko, K., Brown, M. E., & Ketchem, R. R. (2014) · mAbs · doi:10.4161/mabs.36252 · Cited by 20 · see citing works

Prediction and Reduction of the Aggregation of Monoclonal Antibodies

van der Kant, R., Karow‐Zwick, A. R., Durme, J. V., Blech, M., Gallardo, R. U., Seeliger, D., Aßfalg, K., Baatsen, P., Compernolle, G., Gils, A., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.014 · Cited by 149 · see citing works